# Emboline

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emboline

- Industry: Medical Devices & Equipment
- Headquarters: Santa Cruz, US
- Website: www.emboline.com
- Total disclosed funding: $58M
- Latest round: Series D (May 25, 2021)
- Investors on record: 4

## About

Emboline, Inc. is a medical device company focused on enhancing safety during interventional heart procedures, particularly through its innovative Emboliner® Total Embolic Protection Catheter, which aims to mitigate risks associated with transcatheter aortic valve replacement procedures.Founded in 2011 in Santa Cruz, US, Emboline, Inc. specializes in developing medical devices for heart intervention. In March 2026, Emboline, Inc. raised USD 20 million in venture funding. Amir Belson serves as both the CEO and Founder, leading the company through its strategic growth and development.Emboline, Inc. specializes in the development of innovative medical devices designed to enhance safety during interventional heart procedures, particularly the Emboliner® Total Embolic Protection Catheter. This proprietary catheter addresses a significant health risk associated with transcatheter aortic valve replacement (TAVR) procedures—specifically, the release of embolic debris into the bloodstream which can lead to stroke and long-term neurological impairment. The Emboliner® device is designed to capture and remove these emboli before they can affect the brain and other critical organs, providing a crucial layer of protection for patients undergoing TAVR. The company is actively engaged in clinical trials, including the Protect the Head to Head IDE trial, aiming to validate the efficacy and safety of their product. Emboline’s primary market is within the United States, targeting hospitals and medical facilities that perform TAVR procedures, with potential reach extending to international markets as the product gains traction and regulatory approvals.Emboline generates revenue through direct sales of its medical devices, particularly the Emboliner® Total Embolic Protection Catheter, to hospitals and healthcare providers involved in cardiovascular interventions. Transactions typically occur through established contracts with healthcare institutions, which may involve bulk purchasing agreements for usage in specific procedures. The business model is primarily B2B, where hospitals acquire these devices for patient treatments rather than direct-to-consumer sales. Pricing structures for the Emboliner® catheter may involve negotiated rates based on volume, institutional partnerships, and any additional services or support the company provides. The ongoing clinical trials and studies enhance the credibility of the product and create pathways for future sales opportunities as they demonstrate the device's clinical effectiveness and safety in real-world applications.

## Funding rounds

- Series D, May 25, 2021, $55M — Matrix Capital Management, SV Tech Ventures, ShangBay Capital, Global Assets Investment
- Series B, Apr 19, 2018, $3M — SV Tech Ventures, ShangBay Capital

## Investors

- SV Tech Ventures (https://capitalatlas.ai/funds/sv-tech-ventures) — Series B, Series D
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B, Series D
- Matrix Capital Management — Series D
- Global Assets Investment — Series D